BURLINGAME, Calif., Nov. 02, 2016 (GLOBE NEWSWIRE) — Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel immuno-oncology therapies, today announced it will present preliminary clinical and biomarker data from its from its ongoing Phase 1/1b study of CPI-444 as a single agent, and in combination with Genentech’s TECENTRIQ® (atezolizumab), at the Society for Immunotherapy of Cancer’s (SITC) 31st Annual Meeting & Associated Programs taking place November 9 – 13 in National Harbor, Maryland.
Following are the details of Corvus’ two poster presentations:
- Phase 1/1b multicenter trial of CPI-444, an adenosine A2a receptor (A2aR) antagonist as a single agent and in combination with atezolizumab (atezo) in patients with advanced solid tumors (Poster #149)
Authors: John Powderly II1 (presenter), Joshua Brody2, John Nemunaitis3, Leisha Emens4, Jason J. Luke5, Amita Patnaik6, Ian McCaffery7, Richard Miller7, Ginna Laport7
Affiliations: 1Carolina BioOncology Institute, Huntersville, NC; 2Mount Sinai School of Medicine, New York, NY; 3Mary Crowley Cancer Research Center, Gradalis, Inc., Medical City Dallas Hospital, Baylor University Medical Center, Dallas, TX; 4Johns Hopkins School of Medicine, Baltimore, MD; 5University of Chicago School of Medicine; 6 South Texas Accelerated Research Therapeutics, San Antonio, TX, 7Corvus Pharmaceuticals, Burlingame, CA
Session Date and Time: Friday, November 11, 12:15 – 1:30 p.m. and 6:15 – 7:30 p.m. ET
Location: Gaylord National Hotel & Convention Center, Prince George’s Exhibition Hall AB
- CPI-444: a potent and selective inhibitor of adenosine 2A receptor (A2AR) induces anti-tumor responses alone and in combination with anti-PD-L1 (Poster #218)
Authors: Andrew Hotson1 (presenter), Stephen Willingham1, Po Y. Ho1, Carmen Choy1, Ginna Laport1, Ian McCaffery1, Richard Miller1
Affiliations: 1Corvus Pharmaceuticals, Burlingame, CA
Session Date and Time: Saturday, November 12, 11:45 a.m. – 1:00 p.m. and 6:45 – 8:00 p.m. ET
Location: Gaylord National Hotel & Convention Center, Prince George’s Exhibition Hall AB
About Corvus Pharmaceuticals
Corvus Pharmaceuticals is a clinical-stage biopharmaceutical company focused on the development and commercialization of small molecule and antibody agents that target the immune system to treat patients with cancer. These agents block or modify crucial immune checkpoints and reprogram immune T-cells. Corvus’ lead product, CPI-444, is a checkpoint inhibitor that is designed to disable a tumor’s ability to subvert attack by the immune system by inhibiting adenosine in the tumor microenvironment. CPI-444 is a small molecule that is taken orally. CPI-444 is currently being evaluated in a multicenter Phase 1/1b clinical trial in patients with various solid tumors. This successive expansion cohort trial is examining the activity of CPI-444 both as a single agent and in combination with Genentech’s TECENTRIQ (atezolizumab), an anti-PD-L1 antibody. Corvus is conducting the trial with Genentech, a member of the Roche Group, under a clinical trial collaboration the two companies entered into in October 2015. For more information, visit: www.corvuspharma.com.
CONTACT: Investor Contact: Jason Coloma, Ph.D. SVP and Chief Business Officer 650-900-4511 JColoma@corvuspharma.com Media Contact: Julie Normart, W2O Group 415-946-1087 jnormart@w2ogroup.com
